Weave (NYSE: WEAV) has recently appointed Adrian McDermott to its Board of Directors, a move that aims to leverage his three decades of leadership experience in technology and product development. McDermott, who currently serves as the Chief Technology Officer at Zendesk, brings a wealth of expertise in AI-powered customer service solutions and platform scalability, having successfully led the integration of more than a dozen acquired technologies during his tenure at Zendesk.
Weave's Chairperson of the Board, Stuart Harvey, expressed confidence in McDermott's appointment, emphasizing his track record in enterprise software and customer experience platforms, which aligns with Weave's strategic technology initiatives. McDermott's experience in guiding engineering and product teams through rapid growth phases and mergers and acquisitions positions him as an ideal addition to Weave's board as the company continues to expand its market presence.
McDermott's career highlights include holding multiple leadership positions at Zendesk, contributing to the company's growth to over $1 billion in annual revenue. His previous roles include serving as CTO at Attributor and Vice President of Engineering at BEA Systems. McDermott expressed his excitement about joining Weave's board at a pivotal time for the company, citing Weave's mission to help small businesses deliver exceptional customer experiences as a key factor in his decision.
Weave's recent acquisition of TrueLark and its inclusion in G2’s 2025 Best Software Awards for the Best Healthcare Software Products list further underpin the significance of McDermott's appointment, reinforcing Weave's commitment to technological innovation as the company continues to expand its footprint, particularly in multi-location practices.
Weave, a leading all-in-one customer experience and payments software platform for small and medium-sized healthcare businesses, has garnered recognition in the past year as an Inc. Power Partner and a G2 leader in Patient Relationship Management software, highlighting its dedication to transforming how healthcare practices attract, communicate with, and engage patients and clients to grow their business. The market has reacted to these announcements by moving the company's shares 1.23% to a price of $8.21. Check out the company's full 8-K submission here.
